Skip to main content
. Author manuscript; available in PMC: 2019 Jun 1.
Published in final edited form as: Clin Drug Investig. 2018 Jun;38(6):491–501. doi: 10.1007/s40261-018-0639-z

Fig. 4.

Fig. 4

Forest plot from the random-effects model for the association between oral antidiabetic drugs and cardiovascular mortality, comparing different pharmacological drug classes. The results of Zinman et al. [36] (10 and 25 mg) were from one study where cardiovascular safety of two different strengths of empagliflozin were accessed. OR odds ratio, CI confidence interval